Prevention of Bone Mineral Loss by Zoledronic Acid in Men with Prostate Carcinoma Receiving Androgen Deprivation Therapy: A Prospective Randomized Trial in an Indian Population

Publisher： Karger

E-ISSN： 1661-7657|2|2|79-86

ISSN： 1661-7649

Source： Current Urology, Vol.2, Iss.2, 2008-11, pp. : 79-86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Titration of Dosage for the Protective Effect of Zoledronic Acid on Bone Loss in Patients Submitted to Androgen Deprivation Therapy due to Prostate Cancer: A Prospective Open-Label Study

By  

Urologia Internationalis, Vol. 85, Iss. 2, 2010-07 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12‐month randomized controlled trial in men with prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 194-202

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial

By  

Oncology, Vol. 81, Iss. 5-6, 2011-12 ,pp. : 298-305

Karger

Access to resources Recommend Favorite

Determinants of vitamin D levels in men receiving androgen deprivation therapy for prostate cancer

By  

JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS (ELECTRONIC), Vol. 27, Iss. 1, 2015-01 ,pp. : 39-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison

By  

PSYCHO-ONCOLOGY (ELECTRONIC), Vol. 24, Iss. 4, 2015-04 ,pp. : 472-477

John Wiley & Sons Inc

Access to resources Recommend Favorite